Antibiotics can disrupt gut microbiota, leading to potential recurrences of Clostridioides difficile infections (CDI). New therapies like fecal microbiota transplantation (FMT) and monoclonal ...
December 10th 2024EP. 5: Key Data Supporting the Use of Rebyota in Patients With Recurrent C Difficile Infections The panelist discusses Rebyota, a treatment approved by the FDA for preventing ...
Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...
Diagnosis and treatment of CDI represents a challenge to the clinician. As recommended by several guidelines, a key measure for treating CDI ideally includes the discontinuation of concurrent ...
When those bacteria die — for instance, as a result of antibiotic treatment for an unrelated infection — the large intestine becomes vulnerable, and this is often when C. difficile strikes.
The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...
Once C-diff is in the ascendancy it can be very hard to shift – the traditional treatment is antibiotics but a significant number of patients do not respond and are left with relentless and ...